Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Emerging Trends and Therapeutic Innovations in Corneal and Ocular Surface...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Emerging Trends and Therapeutic Innovations in Corneal and Ocular Surface Disorders

A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Ophthalmology".

Deadline for manuscript submissions: 25 February 2027 | Viewed by 1372

Editors

Dr. Zala Lužnik Marzidovšek

E-Mail Website
Guest Editor
1. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
2. Eye Hospital, Ljubljana University Medical Centre, Ljubljana, Slovenia
Interests: cornea; corneal surface disease; corneal transplantation; eye banking; corneal stem cells; corneal immunology
Special Issues, Collections and Topics in MDPI journals
Dr. Špela Štunf Pukl

E-Mail Website
Guest Editor
1. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
2. Eye Hospital, Ljubljana University Medical Centre, Ljubljana, Slovenia
Interests: ophthalmology; cataract; cornea; keratoplasty; ocular surface

Special Issue Information

Dear Colleagues,

We are pleased to announce the launch of our upcoming Special Issue, “Emerging Trends and Therapeutic Innovations in Corneal and Ocular Surface Disorders,” to be featured in the Journal of Clinical Medicine. The cornea and ocular surface are essential for maintaining vision and ocular health, yet they are vulnerable to numerous conditions, including dry eye disease, keratoconus, infectious keratitis, corneal dystrophies, limbal stem cell deficiency, and ocular surface injuries or scarring. These disorders often lead to visual impairment and highlight the need for continued progress in diagnostics and therapy.

This Special Issue invites contributions from researchers, clinicians, and experts exploring cutting-edge developments in the management of corneal and ocular surface diseases. Topics of interest include cell and gene therapies, bioengineered corneal substitutes, nanomedicine-based treatments, regenerative and immunomodulatory strategies, and innovative surgical techniques. Submissions addressing pathophysiology, diagnostic innovations, translational research, or emerging therapeutic modalities are also highly encouraged.

We hope this Special Issue will serve as a platform to disseminate pioneering research, foster multidisciplinary collaboration, and inspire future innovations that enhance clinical outcomes and transform the care of patients with corneal and ocular surface disorders.

Dr. Zala Lužnik Marzidovšek
Dr. Špela Štunf Pukl
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • corneal diseases
  • ocular surface disorders
  • regenerative medicine
  • stem cell therapy
  • gene therapy
  • nanomedicine and targeted drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 1935 KB  
Article
Acceptance of Allogeneic Serum Eye Drops Among Users of Autologous Serum Eye Drops—A Survey-Based Study
by Frank Blaser, Mohammadjavad Abbasi, Mario D. Toro, Timothy Hamann, Daniel Barthelmes, Sandrine A. Zweifel, Martina M. Bosch, Isabelle Meneau, Jana Schneider, Sadiq Said and Vinoth Yogarasa
J. Clin. Med. 2026, 15(17), 6537; https://doi.org/10.3390/jcm15176537 - 24 Aug 2026
Viewed by 225
Abstract
Background/Objectives: To assess the acceptance of, attitudes towards, and concerns regarding allogeneic serum eye drops (Allo-SEDs) among patients treated with autologous serum eye drops (ASEDs). Methods: We conducted this investigator-initiated, cross-sectional, single-center survey at the Department of Ophthalmology, University Hospital Zurich, Switzerland. We [...] Read more.
Background/Objectives: To assess the acceptance of, attitudes towards, and concerns regarding allogeneic serum eye drops (Allo-SEDs) among patients treated with autologous serum eye drops (ASEDs). Methods: We conducted this investigator-initiated, cross-sectional, single-center survey at the Department of Ophthalmology, University Hospital Zurich, Switzerland. We consecutively recruited all patients using ASEDs during routine visits, who anonymously completed a 9-item questionnaire comprising eight 11-point Likert-scale items and one open numerical item on the daily application frequency. We assessed perceived ASED effectiveness, willingness to switch to Allo-SEDs under different scenarios, and concerns regarding safety, efficacy, and immunological risks. Results: Of 202 eligible patients, 107 returned the questionnaire (53.0%). The full eligible cohort had a median (IQR) age of 63.5 (49.2–75.0) years and a median ASED treatment duration of 4.0 (1.0–8.0) years. They rated ASEDs as highly effective (median 9, IQR 8.2–10.0) and applied them a median of 7 (5–10.5) times daily. Willingness to switch was low without clinical need (median 3, IQR 0–6; p = 1.0), increased when autologous production was no longer feasible (median 7, IQR 5–9; p < 0.001), and was intermediate for general openness (median 5, IQR 2–8; p = 0.7). Concerns regarding infectious disease transmission, immunological reactions, and therapeutic efficacy correlated with lower willingness to switch (all r = −0.29 to −0.46). Daily application frequency did not correlate with acceptance. Conclusions: Patients were highly satisfied with ASEDs but were reluctant to switch to Allo-SEDs unless autologous production was no longer feasible. Among the domains assessed, concerns regarding infection, immunological reactions, and efficacy were the main barriers to acceptance, supporting targeted patient education. Full article
(This article belongs to the Special Issue Emerging Trends and Therapeutic Innovations in Corneal and Ocular Surface Disorders)
►▼ Show Figures

Figure 1

Other

Jump to: Research

15 pages, 15276 KB  
Case Report
Masked Corneal Opacity in Bullous Keratopathy: The Impact of Epithelial Pathology on Surgical Decision-Making—A Case Report
by Wojciech Luboń, Łukasz Drzyzga, Wojciech Rokicki and Dorota Wyględowska-Promieńska
J. Clin. Med. 2026, 15(11), 4059; https://doi.org/10.3390/jcm15114059 - 24 May 2026
Viewed by 746
Abstract
Bullous keratopathy may lead to severe corneal opacity and impaired visualization of anterior segment structures, complicating surgical qualification for endothelial keratoplasty (EK). We report the case of a 67-year-old male with pseudophakic bullous keratopathy and Fuchs endothelial dystrophy presenting with clinically complete corneal [...] Read more.
Bullous keratopathy may lead to severe corneal opacity and impaired visualization of anterior segment structures, complicating surgical qualification for endothelial keratoplasty (EK). We report the case of a 67-year-old male with pseudophakic bullous keratopathy and Fuchs endothelial dystrophy presenting with clinically complete corneal opacity and visual acuity limited to hand motion. Slit-lamp examination and anterior segment optical coherence tomography demonstrated marked epithelial remodeling with a dense plaque-like surface lesion obscuring deeper corneal structures. A staged intraoperative approach was undertaken. Following mechanical epithelial debridement, partial restoration of corneal transparency allowed for an intraoperative reassessment of stromal clarity and subsequent Descemet Stripping Automated Endothelial Keratoplasty (DSAEK). Histopathological examination demonstrated reactive epithelial thickening with associated subepithelial fibrosis consistent with chronic bullous keratopathy. Postoperatively, corneal transparency was restored and best-corrected visual acuity improved to 0.7 Snellen (0.15 logMAR), remaining stable during follow-up without graft-related complications or recurrent epithelial abnormalities. This case highlights the importance of considering epithelial contributions to apparent corneal opacity in advanced bullous keratopathy and suggests that staged intraoperative reassessment may support individualized surgical decision-making in selected patients with inconclusive preoperative evaluation. Full article
(This article belongs to the Special Issue Emerging Trends and Therapeutic Innovations in Corneal and Ocular Surface Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop